The newest buying and selling session noticed UnitedHealth Group (UNH) ending at $461.52, denoting a -1.05% adjustment from its final day’s shut. The inventory fell in need of the S&P 500, which registered a lack of 0.5% for the day. Elsewhere, the Dow noticed an upswing of 0.08%, whereas the tech-heavy Nasdaq depreciated by 1.21%.
Shares of the biggest U.S. well being insurer witnessed a lack of 12.41% over the earlier month, trailing the efficiency of the Medical sector with its acquire of two.66% and the S&P 500’s lack of 0.47%.
Market individuals can be intently following the monetary outcomes of UnitedHealth Group in its upcoming launch. The corporate’s upcoming EPS is projected at $7.24, signifying a 4.78% improve in comparison with the identical quarter of the earlier yr. On the identical time, our most up-to-date consensus estimate is projecting a income of $110.97 billion, reflecting a 11.2% rise from the equal quarter final yr.
For your complete fiscal yr, the Zacks Consensus Estimates are projecting earnings of $29.54 per share and a income of $451.19 billion, representing modifications of +6.8% and +12.72%, respectively, from the prior yr.
Traders must also be aware any latest modifications to analyst estimates for UnitedHealth Group. These newest changes typically mirror the shifting dynamics of short-term enterprise patterns. With this in thoughts, we will take into account constructive estimate revisions an indication of optimism in regards to the firm’s enterprise outlook.
Analysis signifies that these estimate revisions are instantly correlated with near-term share value momentum. To capitalize on this, we have crafted the Zacks Rank, a singular mannequin that includes these estimate modifications and provides a sensible score system.
Starting from #1 (Sturdy Purchase) to #5 (Sturdy Promote), the Zacks Rank system has a confirmed, outside-audited monitor file of outperformance, with #1 shares returning a mean of +25% yearly since 1988. Over the previous month, there’s been a 0.65% fall within the Zacks Consensus EPS estimate. Presently, UnitedHealth Group is carrying a Zacks Rank of #3 (Maintain).
With respect to valuation, UnitedHealth Group is at the moment being traded at a Ahead P/E ratio of 15.79. This represents a premium in comparison with its business’s common Ahead P/E of 15.5.
One ought to additional be aware that UNH at the moment holds a PEG ratio of 1.27. This well-liked metric is just like the widely-known P/E ratio, with the distinction being that the PEG ratio additionally takes into consideration the corporate’s anticipated earnings progress charge. Because the market closed yesterday, the Medical – HMOs business was having a mean PEG ratio of 1.
The Medical – HMOs business is a part of the Medical sector. Presently, this business holds a Zacks Trade Rank of 203, positioning it within the backside 20% of all 250+ industries.
The energy of our particular person business teams is measured by the Zacks Trade Rank, which is calculated based mostly on the typical Zacks Rank of the person shares inside these teams. Our analysis exhibits that the highest 50% rated industries outperform the underside half by an element of two to 1.
Be certain to make the most of Zacks.com to observe all of those stock-moving metrics, and extra, within the coming buying and selling classes.
Simply Launched: Zacks High 10 Shares for 2025
Hurry – you possibly can nonetheless get in early on our 10 high tickers for 2025. Handpicked by Zacks Director of Analysis Sheraz Mian, this portfolio has been stunningly and constantly profitable. From inception in 2012 by November, 2024, the Zacks High 10 Shares gained +2,112.6%, greater than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed by 4,400 firms lined by the Zacks Rank and handpicked the very best 10 to purchase and maintain in 2025. You may nonetheless be among the many first to see these just-released shares with huge potential.
UnitedHealth Group Integrated (UNH) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
